These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15009621)

  • 1. Preoperative serum inhibin levels in patients with ovarian tumors.
    El-Shalakany A; Abou-Talib Y; Shalaby HS; Sallam M
    J Obstet Gynaecol Res; 2004 Apr; 30(2):155-61. PubMed ID: 15009621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
    Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total inhibin is a potential serum marker for epithelial ovarian cancer.
    Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
    Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-operative prediction of serum CA125 level in women with ovarian masses.
    Benjapibal M; Neungton C
    J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
    Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
    Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative detection of ovarian cancer by color Doppler ultrasonography and CA 125.
    Hossain F; Karim MN; Rahman SM; Khan N; Siddiqui M; Hussain R
    Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):68-73. PubMed ID: 21473205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascites as a predictor of ovarian malignancy.
    Shen-Gunther J; Mannel RS
    Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neopterin levels in ovarian tumors.
    Park IS; Lee YS; Kim JC; Hwang SG
    Int J Gynaecol Obstet; 1995 Dec; 51(3):229-34. PubMed ID: 8745088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibins and ovarian cancer.
    Robertson DM; Pruysers E; Burger HG; Jobling T; McNeilage J; Healy D
    Mol Cell Endocrinol; 2004 Oct; 225(1-2):65-71. PubMed ID: 15451569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibin A, B and pro-alphaC in serum and peritoneal fluid in postmenopausal patients with ovarian tumors.
    Ala-Fossi SL; Mäenpää J; Bläuer M; Tuohimaa P; Punnonen R
    Eur J Endocrinol; 2000 Apr; 142(4):334-9. PubMed ID: 10754473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibin and CA125 assays in the detection of ovarian cancer.
    Robertson DM; Cahir N; Burger HG; Mamers P; McCloud PI; Pettersson K; McGuckin M
    Clin Chem; 1999 May; 45(5):651-8. PubMed ID: 10222351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.